CoagulationDisorders near Staten Island, NY

Biography: As the Chief of the Maternal Fetal Medicine (MFM) division and the Hillary Rodham Clinton Professor of Women's Health, Dr. Simpson supports a skilled team of physicians with expertise in maternal medicine, critical-care obstetrics, prenatal pediatrics, high-risk deliveries, and research, offering the best maternal and fetal care in the region. She also serves as a leader at CUIMC's Carmen and John Thain Center for Prenatal Pediatrics, where patients with pregnancies complicated by fetal malformations, genetic syndromes, or multiple gestations receive comprehensive, multidisciplinary care in a state-of-the-art facility. As former Director of CUIMC's Ob/Gyn Ultrasound program, she has assembled an outstanding group of sonographers and physicians to provide the best available sonographic imaging to women with high-risk pregnancies. Dr. Simpson's specialized training in fetal echocardiography complements her expertise in prenatal diagnosis. She performs invasive fetal procedures such as chorionic villus sampling, amniocentesis, fetal blood sampling, and others required in complex cases, including, fetoscopy and laser photocoagulation for twin-twin transfusion syndrome. Dr. Simpson has served on the board of directors for the Society of Maternal Fetal Medicine, and was a recipient of the Leonard Tow Humanism in Medicine Award in 2010.

Biography: Dr. Shambavi Richard, MD is a Hematology Specialist who practices in New York, NY. She is 61 years old and has been practicing for 37 years. Dr. Shambavi Richard, MD is affiliated with Mount Sinai Queens, Mount Sinai Hospital and Mount Sinai Morningside.

Care Philosophy: We are committed to delivering the best care and an exceptional patient experience We are devoted to providing services that are patient centered and compassionate and care for you as a person nbsp;

Biography: Myron M. Studner Professor of Cancer Research and Professor of Medicine and Epidemiology at Columbia University, Associate Director for Population Science, Leader of the Prevention, Control, and Disparities Program for the Herbert Irving Comprehensive Cancer Center at Columbia, and Co-Director of the Cancer Prevention Center of New York Presbyterian Hospital Dr. Neugut is a medical oncologist with a particular interest in gastroIntestinal tract cancers, especially of colorectal and gasteric cancers. Under the auspices of Columbia's MD/PhD program, he received his MD and a PhD in Pathobiology in 1977. He did his training in Internal Medicine at the Albert Einstein College of Medicine and fellowship in Medical Oncology at Memorial Sloan-Kettering Cancer Center. He returned to Columbia University as an Andrew Mellon Fellow in Epidemiology and Medicine to obtain an MPH in Epidemiology in 1983. Dr. Neugut then joined the faculty at Columbia University with appointments in Medicine and Epidemiology. As both a practicing medical oncologist and cancer epidemiologist, Dr. Alfred Neugut's major interests have been on GI tract cancers, notably the epidemiology of colorectal adenomas and cancer, as well as colonoscopic screening. He serves as co-principal investigator of the Long Island Breast Cancer Study Project, a large multi-center effort to explore environmental causes of breast cancer on Long Island. Most recently, his efforts have focused on more clinical topics, such as the epidemiology of second malignancies and the use of chemotherapy and radiation therapy among elderly cancer patients. Dr. Neugut focuses a great deal on racial disparities in incidence and survival from cancer and, in particular, variations across subgroups of people of African descent. He leads two large training grants in cancer-related population sciences that together fund 15 pre and postdoctoral trainees in cancer epidemiology, biostatistics, and environmental health sciences, and serves as a mentor to a number of junior faculty.

Care Philosophy: We are committed to delivering the best care and an exceptional patient experience We are devoted to providing services that are patient centered and compassionate and care for you as a person nbsp;

Biography: Dr. Sujit Sheth is the Chiefof the Division of Pediatric Hematology/Oncology and Professor of Clinical Pediatrics at Weill Cornell Medicine andan Attending Pediatrician at NewYork-Presbyterian Phyllis and David Komansky Children's Hospital and Weill Cornell Medical Center. He is also Vice Chair of ClinicalResearch in the Department of Pediatrics at Weill Cornell Medicine.Dr. Shethis board-certified in pediatrics and pediatric hematology/oncology, and is an expert in iron metabolism, thalassemia, and sickle cell disease. Dr. Sheth completed his medical training at the University of Bombay, receiving his medical degree (MBBS) in 1988 and completing his resident specialty training in Pediatrics (MD) in 1991. A year later, he entered Columbia University, College of Physicians & Surgeons as a Post-Doctoral Fellow in Pediatric Hematology/Oncology, completing his fellowship in 1995 and his obligatory additional year of residency in Pediatrics in 1996. Following his residency, Dr. Sheth joined the Columbia University faculty where he was appointed Assistant Professor of Pediatrics. In 2004, he assumed responsibility as Clinical Director of the Pediatric Hematology program, and was promoted to Associate Clinical Professor of Pediatrics. In addition to his clinical work, Dr. Sheth is recognized for his dedication to medical education. At NewYork-Presbyterian Morgan Stanley Children's Hospital, he was voted Attending of the Year by the Pediatric Housestaff in 2010 and nominated for Teacher of the Year eight times, receiving the honor in 1999. He has served on resident selection and education committees, as well as on the Scientific Advisory Board, Irving Center for Clinical Research at NewYork-Presbyterian Hospital.Assuming responsibility as Chief of the Division of Pediatric Hematology and Oncology, Dr. Sheth moved to Weill Cornell in 2011, and was appointed Professor of Clinical Pediatrics in 2012. Since then he has overseen a reorganization and renovation of the Division, practice and clinical facility, adding additional faculty both on the clinical and research arms. Dr. Sheth has also established himself as a physician-scientist with a focus on clinical research related to disorders of iron overload. He has completed work as Principal Investigator on one NIH grant, "Mentored Patient-Oriented Hematology Research Training," and as co-investigator on several other NIH funded studies. He is currently working on research projects and clinical trials related to disorders of red blood cells and iron metabolism. He was appointed Vice-Chair for Clinical Research in 2014, and has worked on improving infrastructure, internal funding and overall support for clinical research in the Department.Related Links:New York Comprehensive Thalassemia Center

Biography: Dr. Hua-Jay "Jeff" Cherng is an assistant professor of medicine in the lymphoma program in the Division of Hematology and Oncology. He earned his medical degree from Case Western Reserve University and completed internal medicine residency at the Hospital of the University of Pennsylvania. He subsequently trained at MD Anderson Cancer Center for his hematology and oncology fellowship. He is board certified in Internal Medicine, Hematology and Medical Oncology. Dr. Cherng is a clinical investigator who researches non-invasive response assessment tools such as biomarkers and imaging to predict outcomes of lymphoma patients. His focus is on circulating tumor DNA (ctDNA), fragments of genetic material shed by lymphomas that can be sequenced and tracked to measure molecular response and minimal residual disease. His work on ctDNA and PET scans in lymphoma has led to publications in high-impact journals including Blood, Blood Advances, American Journal of Hematology, and British Journal of Haematology. He has earned abstract merit awards from the American Society of Hematology, American Society of Clinical Oncology, and Pan Pacific Lymphoma Conference. His accomplishments during fellowship earned him a Waun Ki Hong Award for Achievement in Clinical Investigation. His research on ctDNA in patients with relapsed lymphoma receiving chimeric antigen receptor T-cell therapy is funded by a Conquer Cancer Young Investigator Award grant. He is a member of Southwestern Oncology Group Lymphoma Working Group and Committee. He was selected to participate in the Academy of Next Wave of Investigators for non-Hodgkin's lymphoma and the American Society of Hematology Clinical Research Training Institute, competitive programs aimed at supporting academic and career development for promising clinical researchers. Dr. Cherng's goal is to design clinical trials with treatment guided by ctDNA; this would allow for treatment de-escalation in good responders to minimize toxicity and escalation in poor responders to maximize chance for durable remissions. Dr. Cherng sees patients with all types of lymphoma with an emphasis on aggressive non-Hodgkin B-cell lymphomas. He treats patients with standard-of-care treatments as well as on clinical trial protocols.